Imatinib (Gleevec, Novartis, Basel, Switzerland), formerly referred to as STI571, is an inhibitor of specific protein tyrosine kinases that was targeted to the platelet-derived growth factor (PDGF ...

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference. The study ...

July 26, 2006 —The cardiotoxic effects related to the leukemia drug imatinib ( Gleevec in the United States, Glivec elsewhere; Novartis) "is a big surprise," says the researcher heading the team ...

DFS at 3 years increased from 55% with 3 years of imatinib maintenance to 87% with 6 years of maintenance therapy. Patients with an estimated 35-70% risk of relapse derived the most benefit from ...

Painful crises in sickle cell disease or sickle cell anemia could potentially be treated using imatinib as a therapeutic option, a small study found. Painful crises that occur in patients with ...

Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa.

THE SUCCESS OF the tyrosine kinase inhibitor imatinib mesylate in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) has led to great optimism in the oncology community about ...